TR201720846A2 - ORAL PHARMACEUTICAL COMPONENTS - Google Patents
ORAL PHARMACEUTICAL COMPONENTS Download PDFInfo
- Publication number
- TR201720846A2 TR201720846A2 TR2017/20846A TR201720846A TR201720846A2 TR 201720846 A2 TR201720846 A2 TR 201720846A2 TR 2017/20846 A TR2017/20846 A TR 2017/20846A TR 201720846 A TR201720846 A TR 201720846A TR 201720846 A2 TR201720846 A2 TR 201720846A2
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutically acceptable
- active substance
- acceptable derivatives
- lung diseases
- appropriate
- Prior art date
Links
- 239000005426 pharmaceutical component Substances 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 208000009079 Bronchial Spasm Diseases 0.000 abstract 1
- 208000014181 Bronchial disease Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mevcut buluş; astım, bronşiyal astım, kronik bronşit, kronik obstruktif akciğer hastalığı (KOAH), amfizem ve bronkospazm gibi akciğer hastalıkları ile sekresyonun komplikasyon olarak ortaya çıktığı diğer akciğer hastalıklarının profilaktik ve/veya semptomatik ve/veya terapötik tedavisinde kullanılmak üzere beta-2-adrenerjik reseptör agonisti olan uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin ekspektoran özellikteki uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevleri ile kombine tedavi olarak kullanıldığı farmasötik bileşim/ler ile ilgilidir.The present invention; Beta-2-adrenergic receptor agonist for use in the prophylactic and / or symptomatic and / or therapeutic treatment of lung diseases such as asthma, bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema and bronchospasm, and other lung diseases in which secretion occurs as a complication relates to the pharmaceutical composition (s) in which the appropriate active substance and / or its pharmaceutically acceptable derivatives are used as combination therapy with the appropriate expectorant active substance and / or pharmaceutically acceptable derivatives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/20846A TR201720846A2 (en) | 2017-12-19 | 2017-12-19 | ORAL PHARMACEUTICAL COMPONENTS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/20846A TR201720846A2 (en) | 2017-12-19 | 2017-12-19 | ORAL PHARMACEUTICAL COMPONENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201720846A2 true TR201720846A2 (en) | 2019-07-22 |
Family
ID=67901276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2017/20846A TR201720846A2 (en) | 2017-12-19 | 2017-12-19 | ORAL PHARMACEUTICAL COMPONENTS |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR201720846A2 (en) |
-
2017
- 2017-12-19 TR TR2017/20846A patent/TR201720846A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430920B1 (en) | P2X3 aminoquinazoline derivatives as inhibitors | |
| EP4591936A3 (en) | Treatment of respiratory diseases | |
| BRPI0819932A2 (en) | composition, use of a composition, nebulizer, inhaler or intranasal device, processes for producing a pharmaceutical composition and a polypeptide composition, and use of a physiologically acceptable buffer. | |
| EA201991793A1 (en) | Tyrosinamide derivatives as rho kinase inhibitors | |
| EP4620525A3 (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | |
| BR112015006571A2 (en) | pharmaceutical composition, process for preparing a pharmaceutical composition, use of a pharmaceutical composition, and method for the prophylaxis or treatment of asthma, chronic obstructive pulmonary disease and related respiratory disorders | |
| EA201270561A1 (en) | CGRP RECEPTOR ANTAGONISTS | |
| EA202092976A1 (en) | SUSTAINABLE PHARMACEUTICAL COMPOSITIONS FOR PRESSURE DOSED INHALERS | |
| ZA202212128B (en) | Combination of alcaftadine and a corticosteroid | |
| EA201201397A1 (en) | INHALER CONTAINING DISTRIBUTED GLISTER PACKING | |
| PH12017502087B1 (en) | Tiotropium inhalation solution for nebulization | |
| UA100777C2 (en) | Inhalable particles comprising tiotropium | |
| MX2024010140A (en) | NEW METHODS. | |
| EA201590019A1 (en) | DRY POWDER INHALERS, CARRIER CONTAINING, EXCELLENT FROM LACTOSE | |
| WO2011093819A3 (en) | New pharmaceutical combination comprising tiotropium | |
| ZA202308388B (en) | Nasal compositions comprising alcaftadine | |
| WO2011093820A3 (en) | A pharmaceutical combination comprising tiotropium | |
| BR112021020279A2 (en) | Pyridopyrimidine derivatives as p2x3 inhibitors | |
| MX2023005801A (en) | PHTHALAZINE DERIVATIVES AS P2X PURINOCEPTOR 3 (P2X3) INHIBITORS. | |
| CL2008000973A1 (en) | Compounds derived from 1-oxo-isoquinoline; preparation procedure; pharmaceutical composition; and its use in the treatment of chronic obstructive pulmonary diseases (COPD) and asthma. | |
| EA201201389A1 (en) | INHALER, CREATING TURBULENCE | |
| MX373699B (en) | PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL. | |
| MX368036B (en) | Inhalable particles comprising tiotropium and indacaterol. | |
| UA115989C2 (en) | Dry powder inhaler compositions comprising long acting muscorinic antagonists | |
| TR201720845A1 (en) | ORAL PHARMACEUTICAL COMPONENTS |